^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    CBP-1018

    i
    Other names: CBP-1018
    Associations

    News

    Trials
    Company:
    Coherent Biopharma
    Drug class:
    Tubulin inhibitor, PSMA inhibitor, Folate receptor 1 inhibitor
    Related drugs:
    Associations

    News

    Trials
    3ms
    A Study of CBP-1018 in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=170, Recruiting, Coherent Biopharma (Suzhou) Co., Ltd. | Trial primary completion date: Dec 2023 --> Oct 2024
    Trial primary completion date • Metastases
    |
    FOLR1 ( Folate receptor alpha )
    |
    CBP-1018
    4ms
    LC-MS/MS method for dual-ligand peptide-drug CBP-1018 and its deconjugated payload MMAE including sample stabilization strategy for its MC-Val-Cit-PABC linker. (PubMed, Talanta)
    The results showed that CBP-1018 was eliminated immediately after injection and MMAE reached the maximum exposure at approximately 2 h after infusion. The maximum concentration of MMAE did not exceed 20.0 ng/mL, suggesting that the off-target toxicity of CBP-1018 injection was controllable.
    Journal
    |
    CTSS (Cathepsin S)
    |
    CBP-1018
    over1year
    Bispecific-XDC: Novel First-in-Class Cancer Therapies From Concept to Clinical (ADC-USA 2023)
    Describing CBP-1008: a FR/ TRPV6 targeted drug conjugate in Phase II pivotal studies of advanced ovarian cancer treatment; Exploring CBP-1018: a FR/ PSMA targeted drug conjugate in Phase Ib for prostate cancer therapy; Highlighting CBP-1019: TOP1i payload drug conjugate for unmet medical needs
    Clinical
    |
    TRPV6 (Transient Receptor Potential Cation Channel Subfamily V Member 6)
    |
    CBP-1008 • CBP-1018 • CBP-1019
    over1year
    CBP-1018, a bi-ligand-drug conjugate treated in patients with advanced solid tumors: A phase I, multi-center, open-label, dose-escalation and dose expansion study (ESMO 2023)
    Multiple SD and PSA decrease were observed at DLs of 0.08-0.14 mg/kg, conferred a promising preliminary antitumor activity in pts with mCRPC despite of COVID-19's impacts. MTD was not reached and dose-escalation to establish the RP2D is continuing.
    Clinical • Metastases
    |
    FOLR1 ( Folate receptor alpha )
    |
    CBP-1018